Triple-Drug cocktail shows promise in early prostate cancer trial
NCT ID NCT04477512
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tested a combination of three drugs—cabozantinib, abiraterone, and nivolumab—in 18 men with metastatic hormone-sensitive prostate cancer that had not yet been treated. The main goal was to find a safe dose and check for serious side effects. Researchers also looked at whether the treatment could lower PSA levels and shrink tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Cabozantinib, abiraterone acetate, nivolumab, and prednisone
What this could lead to
If this combination proves safe and effective, it could offer a new treatment option for men with metastatic hormone-sensitive prostate cancer.
What could go wrong
This is a very early (phase 1) trial with only 18 participants, so results may not apply to everyone. The drug combination also carries risks of serious side effects like immune-related reactions.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC HORMONE-SENSITIVE PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States